6. Resistance to Bcl-2 Targeting Therapy Depends on Both Specific Molecular Mechanisms Associated with Monocytic AML Cell Differentiation, as Well as General Susceptibility Biomarkers Identified in Previous Studies of Conventional Anti-AML Therapy. The gene discussed is BCL2; the disease is acute myeloid leukemia.